Pharmacology  ·  Anti-Seizure Drugs

Seizure Classification & Drug Mechanisms

A visual summary of seizure types and anti-seizure drug categories

• Anti-seizure drug selection is determined by seizure type, not by physician preference or drug availability. The classification panels come first in the infographic because prescribing before classifying correctly is the most common and consequential error in epilepsy pharmacology.
• The focal versus generalized distinction maps directly onto drug selection. Focal seizures respond to a wide range of agents. Generalized seizures, particularly absence and myoclonic, are worsened by sodium channel blockers — the same drugs that are first-line for focal epilepsy. Misclassification in this direction can increase seizure frequency.
• The four mechanism cards show that every anti-seizure drug in clinical use reduces neuronal excitation through one of two targets (sodium channels, calcium channels) or increases inhibition through one of two routes (gamma-aminobutyric acid enhancement, glutamate blockade). Valproate appears in two of the four categories because it acts through multiple mechanisms simultaneously, which explains its broad spectrum.
• The two syndrome cards translate the mechanistic framework into clinical decisions. Childhood absence epilepsy uses ethosuximide because the pathological rhythm originates in thalamic T-type calcium channels — exactly the target ethosuximide blocks. Sodium channel blockers don't reach that target and make absence worse. Juvenile myoclonic epilepsy uses valproate because it covers myoclonic, tonic-clonic, and absence components simultaneously.
• The rule box at the bottom reframes the whole page as a safety rule: correct seizure classification before prescribing is not a procedural preference but a patient safety requirement, because the wrong choice actively harms.